Patients' goals when initiating long-acting injectable buprenorphine treatment for opioid use disorder: findings from a longitudinal qualitative study.
Abstinence
Long-acting Injectable Buprenorphine
Longitudinal
Opioid use disorder
Person-Centred Care
Qualitative
Recovery
Substance use
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
22 Jun 2023
22 Jun 2023
Historique:
received:
02
05
2023
accepted:
16
06
2023
medline:
26
6
2023
pubmed:
23
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Long-acting injectable buprenorphine (LAIB) is a new treatment for opioid use disorder that has been introduced against an international policy backdrop of recovery and person-centred care. This paper explores the goals that people want to achieve from LAIB to identify potential implications for policy and practice. Data derive from longitudinal qualitative interviews conducted with 26 people (18 male; 8 female) initiating LAIB in England and Wales, UK (June 2021-March 2022). Participants were interviewed up to five times by telephone over six months (107 interviews in total). Transcribed interview data relating to each participant's treatment goals were coded, summarised in Excel, and then analysed via a process of Iterative Categorization. Participants often articulated a desire to be abstinent without defining exactly what they meant by this. Most intended to reduce their dosage of LAIB but did not want to rush. Although participants seldom used the term 'recovery', almost all identified objectives consistent with current definitions of this concept. Participants articulated broadly consistent goals over time, although some extended the timeframes for achieving treatment-related goals at later interviews. At their last interview, most participants remained on LAIB, and there were reports that the medication was enabling positive outcomes. Despite this, participants were aware of the complex personal, service-level, and situational factors that hindered their treatment progress, understood the additional support they needed to achieve their goals, and voiced frustrations when services failed them. There is a need for wider debate regarding the goals people initiating LAIB are seeking and the diverse range of positive treatment outcomes LAIB could potentially generate. Those providing LAIB should offer regular on-going contact and other forms of non-medical support so that patients have the best opportunity to succeed. Policies relating to recovery and person-centred care have previously been criticised for responsibilising patients and service users to take better care of themselves and to change their own lives. In contrast, our findings suggest that these policies may, in fact, be empowering people to expect a greater range of support as part of the package of care they receive from service providers.
Sections du résumé
BACKGROUND
BACKGROUND
Long-acting injectable buprenorphine (LAIB) is a new treatment for opioid use disorder that has been introduced against an international policy backdrop of recovery and person-centred care. This paper explores the goals that people want to achieve from LAIB to identify potential implications for policy and practice.
METHODS
METHODS
Data derive from longitudinal qualitative interviews conducted with 26 people (18 male; 8 female) initiating LAIB in England and Wales, UK (June 2021-March 2022). Participants were interviewed up to five times by telephone over six months (107 interviews in total). Transcribed interview data relating to each participant's treatment goals were coded, summarised in Excel, and then analysed via a process of Iterative Categorization.
RESULTS
RESULTS
Participants often articulated a desire to be abstinent without defining exactly what they meant by this. Most intended to reduce their dosage of LAIB but did not want to rush. Although participants seldom used the term 'recovery', almost all identified objectives consistent with current definitions of this concept. Participants articulated broadly consistent goals over time, although some extended the timeframes for achieving treatment-related goals at later interviews. At their last interview, most participants remained on LAIB, and there were reports that the medication was enabling positive outcomes. Despite this, participants were aware of the complex personal, service-level, and situational factors that hindered their treatment progress, understood the additional support they needed to achieve their goals, and voiced frustrations when services failed them.
CONCLUSIONS
CONCLUSIONS
There is a need for wider debate regarding the goals people initiating LAIB are seeking and the diverse range of positive treatment outcomes LAIB could potentially generate. Those providing LAIB should offer regular on-going contact and other forms of non-medical support so that patients have the best opportunity to succeed. Policies relating to recovery and person-centred care have previously been criticised for responsibilising patients and service users to take better care of themselves and to change their own lives. In contrast, our findings suggest that these policies may, in fact, be empowering people to expect a greater range of support as part of the package of care they receive from service providers.
Identifiants
pubmed: 37349776
doi: 10.1186/s13011-023-00551-0
pii: 10.1186/s13011-023-00551-0
pmc: PMC10288705
doi:
Substances chimiques
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
37Informations de copyright
© 2023. The Author(s).
Références
Addiction. 2017 Mar;112(3):386-387
pubmed: 27561982
Int J Drug Policy. 2011 May;22(3):189-93
pubmed: 21055914
Int J Drug Policy. 2017 Jun;44:174-182
pubmed: 28511843
J Interprof Care. 2019 Nov-Dec;33(6):734-743
pubmed: 30526196
J Stud Alcohol. 1994 Mar;55(2):159-66
pubmed: 8189736
Subst Use Misuse. 2008;43(12-13):1971-86
pubmed: 19016174
Drug Alcohol Rev. 2019 Jul;38(5):510-518
pubmed: 31131514
Alcohol Res. 2020 Sep 24;40(3):01
pubmed: 32983748
Drug Alcohol Depend. 2016 Aug 01;165:159-67
pubmed: 27344196
Addiction. 2023 Jul;118(7):1329-1339
pubmed: 36808168
Health Expect. 2009 Dec;12(4):347-60
pubmed: 19689450
Drug Alcohol Depend. 2021 Oct 1;227:108959
pubmed: 34450472
Addiction. 2020 Jul;115(7):1295-1305
pubmed: 31860767
JAMA Intern Med. 2018 Jun 1;178(6):764-773
pubmed: 29799968
Int J Drug Policy. 2021 Nov;97:103357
pubmed: 34280606
Int J Drug Policy. 2022 Feb;100:103492
pubmed: 34736130
Int J Drug Policy. 2015 Jul;26(7):617-25
pubmed: 25962733
Subst Abuse Treat Prev Policy. 2022 May 25;17(1):40
pubmed: 35614466
J Subst Abuse Treat. 2019 Sep;104:64-71
pubmed: 31370986
Addiction. 2016 Jun;111(6):1096-106
pubmed: 26806155
Addiction. 2006 Mar;101(3):420-32
pubmed: 16499515
J Subst Abuse Treat. 2020 Apr;111:54-66
pubmed: 32076361
Am J Psychiatry. 2022 Nov 1;179(11):807-813
pubmed: 35410494
Addiction. 2021 Mar;116(3):668-676
pubmed: 32926762
Harm Reduct J. 2019 Apr 3;16(1):25
pubmed: 30943990